Inpex to Delay Decision on Ichthys LNG to Late 2010
Australian Oil Industry Sees Blow to Reputation From Spill
Aetna Contract to Get Defense Department Review
WellPoint, Humana Find GOP Wins Make for Good Day
UBS Gets Fewest ‘Buys’ as Analysts Fret Over Fleeing Clients
Morgan Stanley Hires Six From UBS for Wealth Unit
Penn National Advances After Ohio Approves Casinos
Agilysys, Charles River, Molson Coors, PMA: U.S. Equity Movers
Cinemark Sues Imax Over Theater Conversion Patents
Health Insurers Rally Most in S&P 500 on Elections
Centro Seeks Restructuring Options From Bankers, Review Reports
Chrysler Aims to Increase Jeep Global Sales 60 Percent by 2014
Anglo Irish Bank May Axe Around 460 Jobs in Cost-Cutting Plan
Access International’s Littaye Charged in Madoff Case
Italian Stocks: Ansaldo, Banca Generali, Exor, Fiat, Tenaris
Cinemark Sues Imax Over Movie Theater Conversion Patents
Chrysler Says It Has Added $1.7 Billion in Cash Since June
GM Battles Worker, German Resistance in Opel Rescue
U.K. Needs Representation on EU Risk Board, Paul Myners Says
Ohio Voters Approve Ballot Measure Allowing Casinos
Astana Finance’s Domestic Creditors Reject Restructuring Plan
Liz Claiborne Amends Revolving Credit Facility (Update1)
Russia May Halve 2010 Planned Debt Sale as Oil Price Kicks In
Belo Plans to Sell Notes as Debt Returns Outpace Equity
Palm Oil Jumps to Highest in More Than 2 Months as Crude Gains
U.K. Consumer Confidence Holds at 1 1/2-Year High
Latin Day Ahead: Bradesco Third-Quarter Net Falls on Defaults
Alvarion Gains Most in Seven Weeks on Lower-Than-Expected Loss
European Manufacturing, Services Expanded in October
Toyota to Withdraw From Formula One to Reduce Costs
British Airways Raised to ‘Buy’ From ‘Neutral’ at UBS
National Australia Pulls Bond Sale Citing Standards
Australia, PTTEP to Probe Timor Sea Oil Spill, Blaze
Zumtobel Raised to ‘Buy’ From ‘Neutral’ at UBS
Virginia Elects Republican Governor in Setback for Obama
Malaysia Stocks: Faber, Lityan, Maybank, RHB, Scomi, Time
Breast Cancer Vaccine Tests German Merck’s $1 Billion Strategy
